17:08 , Mar 14, 2019 |  BC Extra  |  Company News

Mammoth in-licenses CRISPR-Cas14 IP

Mammoth exclusively licensed IP covering one of the newest families of CRISPR enzymes, Cas14, from the University of California Berkeley. The new license adds a third group of CRISPR enzymes to the diagnostics company's toolbox....
14:34 , Mar 14, 2019 |  BioCentury  |  Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...
22:15 , Mar 11, 2019 |  BC Extra  |  Company News

CF negotiations will continue next week

Vertex’s Jeffrey Leiden and U.K. Health Secretary Matthew Hancock have agreed to meet again next week to continue discussions on the availability of the biotech's cystic fibrosis drugs in the U.K. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)...
02:24 , Mar 9, 2019 |  BioCentury  |  Politics, Policy & Law

Top-down solution to the U.K. Orkambi debacle

Cystic fibrosis patients hope that a meeting on Monday between Vertex and the U.K. Health Secretary will break the deadlock that has prevented reimbursement of Orkambi by NHS. If it works out, patients in England...
18:32 , Mar 7, 2019 |  BC Extra  |  Company News

Vertex proposal provides hope of breaking CF impasse

Vertex plans to propose providing immediate access to its products to England’s cystic fibrosis patients while it negotiates reimbursement with the U.K. government. Chairman, President and CEO Jeffrey Leiden told MPs that in his meeting...
20:31 , Mar 6, 2019 |  BC Extra  |  Clinical News

Ahead of House of Commons meeting, another Vertex triple CF combo meets in Phase III

A day before Parliament's House of Commons Health and Social Care Committee is scheduled to hold a public hearing on the availability and pricing of Vertex's portfolio of cystic fibrosis drugs, the biotech announced that...
20:42 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

CRISPR, Vertex dose first β-thalassemia patient, begin enrolling sickle cell patients in Phase I trials of CRISPR therapy

CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) dosed the first patient in a Canadian and European Phase I/II trial of CTX001 to treat transfusion-dependent β-thalassemia, and enrolled the first patient in a U.S....
19:38 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Vertex's tezacaftor/ivacaftor meets in Phase III for pediatric CF

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said tezacaftor/ivacaftor met the primary endpoint of improving the absolute change in lung clearance index in a double-blind, European and Australian Phase III trial to treat children with cystic fibrosis. In...
17:50 , Feb 13, 2019 |  BC Week In Review  |  Company News

Vertex gets Priority Review voucher from Symdeko approval

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it received a Priority Review voucher on Jan. 29 from FDA based on the February 2018 approval of Symdeko tezacaftor/ivacaftor to treat cystic fibrosis in patients ages 12 and older....
13:25 , Feb 8, 2019 |  BioCentury  |  Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...